Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Phase 3RezpegaldesleukinPositive

AI Analysis

Summary

Nektar Therapeutics announced the initiation of two global Phase 3 registrational trials (ZENITH AD program) evaluating rezpegaldesleukin for moderate-to-severe atopic dermatitis, based on positive efficacy and safety data from a 393-patient Phase 2b study.

Clinical Trial Data

Phase

Phase 3

Patients

393

Outcome Details

Phase 3 ZENITH AD program initiation based on Phase 2b efficacy and safety data

Importance:7/10

Sentiment:

0.70

Phase 3Atopic DermatitisRegulatory T-Cell BiologicClinical Trial Initiation

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on July 21, 2026 11:00 AM

Read Original